Introduction
Worldwide, there are over 500,000 new cases of head and neck cancer each year, making this group of tumours the 6th most common malignancy in men and 9th most common in women [1] . Two thirds of patients with head and neck cancer will present with local or regionally advanced disease, however, surgery and radiotherapy are the mainstays of treatment as the main management issue is local tumour control [2] . Surgery, in particular, may be disfiguring and disabling, especially with squamous-cell carcinomas of the larynx and tongue, and even with optimal therapy locoregional recurrence is common. Once tumour relapse occurs the disease is not usually amenable to curative therapy. More effective systemic treatments could lead to enhanced local control, permit less extensive and disfiguring local treatments and provide superior palliation for patients with advanced or metastatic disease.
Raltitrexed ('Tomudex') is a folate based specific inhibitor of thymidylate synthase (TS) which has been shown to be equivalent, in terms of survival, to 5-fluorouracil (5-FU) and folinic acid in two of three large randomised phase III studies in patients with advanced colon cancer [3] . 5-FU has activity in head and neck cancer, as does methotrexate, another folate based anticancer drug. The current study was initiated following the demonstration in a European phase I study of responses to raltitrexed in patients with chemotherapy resistant head and neck cancer [4] .
Patients and methods
This multi-centre, phase II study targeted chemotherapy naive patients with incurable squamous-cell carcinoma derived from head and neck sites apart from skin. Patients were enrolled from seven Australian teaching hospitals. The study end points were the response rate and safety of raltitrexed in the target population. The inclusion criteria were the demonstration of incurable, histologically confirmed squamous-cell carcinoma with one or more bidimensionally measurable lesions, age 5 18 years, WHO performance status (PS) ^ 2, life expectancy > 12 weeks and written informed consent. Patients were required to have adequate haematology (white blood count > 4 x 1O 9 /1 and platelet count < 100 x 10 therapy to >25% of bone marrow (and within the previous eight weeks), or if there was history of prior malignancy, cerebral metastases or treatment with folic acid supplementation. Further exclusions were the presence of uncontrolled infection or other serious medical condition, and pregnancy or breast-feeding. Raltitrexed was administered intravenously as a 15-minute infusion every 3 weeks and treatment planned for at least 6 courses in the absence of disease progression or unacceptable toxicity and up to a maximum of 12 courses in patients showing evidence of response. Disease assessment was performed after every two cycles and response characterised according to standard UICC criteria [5] . Toxicity assessment was undertaken prior to each cycle of treatment and graded according to WHO criteria [6] . Dose reductions were planned for severe toxicities.
Results
From November 1996 to December 1998, 24 patients were entered into the study. The patient demographic details are shown in Table 1 . Three patients (13%) had metastases to either lung or bone and six others (25%) had distant soft tissue/lymph node metastases while the remaining patients (63%) had recurrent locoregional disease only.
Twelve patients (50%) received only one cycle of raltitrexed. In nine of these there was early progression of disease. In a further two patients, treatment was stopped after one cycle at the discretion of the treating physician because the patients were too unwell, but without definite evidence of disease progression or treatment related toxicity. The twelfth patient refused further treatment. There was no requirement for dose delay and only one patient required a dose reduction following a decrease in creatinine clearance which occurred after five cycles of treatment and which was not definitely drug related. This patient ultimately received eight cycles of raltitrexed, without further deterioration in renal function. No significant neutropenia or thrombocytopenia was encountered. The liver function test abnormalities that occurred in 11 patients were manifest by an asymptomatic, transient elevation of transaminases. No patient experienced jaundice or progressive hepatic impairment. The non-haematological toxicities are summarised in Table 2 . Nausea and vomiting were easily controlled with anti-emetics, such as metoclopramide. Two patients died on study, both due to progressive malignancy. However, one of these died from aspiration pneumonia while recovering from grade 3 diarrhoea.
No patient achieved a response to raltitrexed, although five patients experienced stable disease for a median of 188 days (range 61-436). For all patients, the median time to progression was 41 days (range 13-436) and the median survival was 101 days (range 20-436).
Discussion
Raltitrexed was well tolerated in this patient population with no patient requiring a delay in treatment administration. Furthermore, dose reduction was only required in one patient, due to a fall in creatinine clearance. Significant myelosuppression and diarrhoea were not seen, although this may have been due to the fact that 50% of the patients received only one cycle of treatment. The toxicities associated with raltitrexed have raised some concerns recently following the presentation of a phase III colorectal cancer study at the 1999 American Society of Clinical Oncology (ASCO) meeting, which reported a 4% death rate for patients treated with raltitrexed [7] . The cause of death was a combination of severe diarrhoea and myelosuppression [7] although some affected patients were apparently not treated according to prescribing information guidelines. The extent of toxicity was also in excess of that seen in previous phase III studies [8] . Head and neck cancer patients are often poorly nourished and could be expected to fare worse than patients with other tumour types when treated with folate based drugs because of lower intracellular folate pools. The paucity of toxicity reported in the current study is reassuring for the widespread use of raltitrexed, particularly as many of the patients treated were poorly nourished.
This study failed to demonstrate significant activity for raltitrexed in patients with advanced recurrent or metastatic head and neck cancer, albeit in a population which was fairly heavily pre-treated with surgery and radiotherapy, and in which the majority of patients had locoregional recurrence only. The nature of the population treated in this study is reflected by the short median survival (101 days).
The lack of response is disappointing given that other anti-metabolites, including TS inhibitors, have demonstrated activity in patients with head and neck cancer. For example, 5-FU given as a single agent, has a response rate of 15% in first-line treatment of advanced disease [9] and 30%, second line, when combined with folinic acid [10] . There is also evidence from randomised combination studies that 5-FU administered by continuous infusion produces higher response rates than bolus regimens [11] . The reported response rates for methotrexate, administered as a single agent to large numbers of patients with head and neck cancer treated in phase II trials, have been around 30%, and this agent remains the palliative treatment of choice in this condition [12] . Significantly, however, two recent, large phase III trials comparing methotrexate to other single-agent and combination treatments have demonstrated response rates of only 6% and 10% for patients treated on the methotrexate arms [13, 14] . This apparent disparity suggests that patient selection may be an important determinant of response in this condition.
LY231514 (MTA) is another inhibitor of thymidylate synthase, but also has activity against other folate based enzymes including dihydrofolate reductase and glycinamide ribonucleotide formyltransferase. In a recent phase II study of MTA in head and neck cancer patients a response rate of 33% was reported in 27 patients [15] . The population treated in this study was somewhat atypical for head and neck cancer patients in that the median age was only 51 years and 24 of 27 patients (89%) treated had distant metastatic disease [15] .
Thus, the response rates to chemotherapy in head and neck cancer may vary significantly depending on the patient population treated, particularly with reference to parameters such as median age, performance status, disease site and extent of prior therapy. However, the results of the current study do not warrant further development of raltitrexed as monotherapy for this indication. Encouraging activity has been seen with combinations of raltitrexed and other active cytotoxic drugs in various tumour types. It remains to be established if such combination therapies have value in head and neck cancer.
